1. Home
  2. NAMS vs STNE Comparison

NAMS vs STNE Comparison

Compare NAMS & STNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • STNE
  • Stock Information
  • Founded
  • NAMS 2019
  • STNE 2012
  • Country
  • NAMS Netherlands
  • STNE Cayman Islands
  • Employees
  • NAMS N/A
  • STNE N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • STNE EDP Services
  • Sector
  • NAMS Health Care
  • STNE Technology
  • Exchange
  • NAMS Nasdaq
  • STNE Nasdaq
  • Market Cap
  • NAMS 2.5B
  • STNE 3.9B
  • IPO Year
  • NAMS N/A
  • STNE 2018
  • Fundamental
  • Price
  • NAMS $19.85
  • STNE $16.18
  • Analyst Decision
  • NAMS Strong Buy
  • STNE Buy
  • Analyst Count
  • NAMS 8
  • STNE 8
  • Target Price
  • NAMS $42.88
  • STNE $15.63
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • STNE 6.0M
  • Earning Date
  • NAMS 08-06-2025
  • STNE 08-13-2025
  • Dividend Yield
  • NAMS N/A
  • STNE N/A
  • EPS Growth
  • NAMS N/A
  • STNE N/A
  • EPS
  • NAMS N/A
  • STNE N/A
  • Revenue
  • NAMS $47,140,000.00
  • STNE $2,314,839,446.00
  • Revenue This Year
  • NAMS N/A
  • STNE $24.21
  • Revenue Next Year
  • NAMS N/A
  • STNE $7.09
  • P/E Ratio
  • NAMS N/A
  • STNE N/A
  • Revenue Growth
  • NAMS 586.97
  • STNE 12.87
  • 52 Week Low
  • NAMS $14.06
  • STNE $7.72
  • 52 Week High
  • NAMS $27.29
  • STNE $16.32
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 52.90
  • STNE 65.61
  • Support Level
  • NAMS $17.97
  • STNE $15.64
  • Resistance Level
  • NAMS $19.13
  • STNE $16.32
  • Average True Range (ATR)
  • NAMS 1.04
  • STNE 0.57
  • MACD
  • NAMS -0.03
  • STNE 0.11
  • Stochastic Oscillator
  • NAMS 35.63
  • STNE 94.83

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About STNE StoneCo Ltd.

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

Share on Social Networks: